Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Shang-Gin Wu, Yih-Leong Chang, Chong-Jen Yu, Pan-Chyr Yang, Jin-Yuan Shih. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016

Member's Comments

No comment yet.

Related content which might interest you: EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Better quality-of-life in patients with exon 19 deletion receiving first-line tyrosine kinase inhibitors for advanced non-small-cell lung cancer Source: International Congress 2017 – Noteworthy lung cancer patient reports: reported outcome measures, smoking cessation, weight and sleep disorders Year: 2017 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 RON tyrosine kinase mutations in brain metastases from lung cancer Source: ERJ Open Res, 4 (1) 00083-2017; 10.1183/23120541.00083-2017 Year: 2018 European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Outcomes of NSCLC patients with positive EGFR mutation Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1551 Year: 2012 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1550-1551 Year: 2012